$25.47
0.321.27%
Last update: Nov 11, 9:30 AM
Beam Therapeutics Inc
BEAMNASDAQ
Beam Therapeutics rose 11.9% from $22.48 to $25.15, ahead of the S&P 500's +9.8%. Its worst day was Jun 5 (−10.5%), and its low came Nov 20 at $20.60.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Beam Therapeutics closed at its lowest level of the year, 8.4% below where the year started.
−1.8% · S&P 500 −1.5%
Story events cover the past 12 months · Times ET
Beam Therapeutics shares rose 22.3%, while the S&P 500 rose 0.2%.
+22.3%, the year's best day, on 7M shares, the year's heaviest volume · S&P 500 +0.2%
EPS of $-0.10 beat the $-1.12 estimate on $114.1M revenue (est. $13.6M).
+14.0% · S&P 500 +0.7%
EPS of $-0.91 beat the $-0.98 estimate on $31.7M revenue (est. $13.9M).
−2.7% · S&P 500 −0.3%
Beam Therapeutics closed at its highest level of the year, 68.7% above where the year started.
+7.4% · S&P 500 −0.5%
EPS of $-1.18 missed the $-1.11 estimate on $490,000.00 revenue (est. $18.9M).
+9.4% · S&P 500 +1.8%
EPS of $-1.28 missed the $-1.17 estimate on $307,000.00 revenue (est. $10.2M).
+1.8% · S&P 500 +0.3%
Where it ended: a close of $25.15 on Nov 10, 2026. Up next: Q4 2026 earnings on Feb 23, 2027 (EPS est. $-1.23, revenue est. $5.2M).
Nothing in the past 12 months.
All BEAM dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BEAM and SPY from Benzinga historical bars. Not investment advice.
